Skip to main content

Lund University Publications

LUND UNIVERSITY LIBRARIES

Upregulated levels of human β-defensins in patients with seasonal allergic rhinitis after allergen-specific immunotherapy treatment.

Bogefors, Jesper ; Kvarnhammar, Anne Månsson and Cardell, Lars-Olaf LU (2013) In International Forum of Allergy & Rhinology 3(2). p.99-103
Abstract
BACKGROUND: Antimicrobial peptides (AMPs) are important actors in the innate immune system. One class of AMPs is the human β-defensins (HBDs), a group of small peptides with a broad spectrum of antimicrobial activities. Expression of HBDs is downregulated in different manifestations of allergic disease. In this study, we examine whether allergen-specific immunotherapy (ASIT) affects the nasal levels of HBDs in patients with seasonal allergic rhinitis (SAR). METHODS: Nasal biopsies were examined for the occurrence of HBD1-3 with real-time reverse-transcription polymerase chain reaction (RT-PCR) and immunohistochemistry. Nasal lavage (NAL) fluids from healthy individuals, untreated SAR patients and SAR patients before and after ASIT were... (More)
BACKGROUND: Antimicrobial peptides (AMPs) are important actors in the innate immune system. One class of AMPs is the human β-defensins (HBDs), a group of small peptides with a broad spectrum of antimicrobial activities. Expression of HBDs is downregulated in different manifestations of allergic disease. In this study, we examine whether allergen-specific immunotherapy (ASIT) affects the nasal levels of HBDs in patients with seasonal allergic rhinitis (SAR). METHODS: Nasal biopsies were examined for the occurrence of HBD1-3 with real-time reverse-transcription polymerase chain reaction (RT-PCR) and immunohistochemistry. Nasal lavage (NAL) fluids from healthy individuals, untreated SAR patients and SAR patients before and after ASIT were analyzed for levels of HBD1-3 using enzyme-linked immunosorbent assay (ELISA). RESULTS: Examination of nasal biopsies revealed HBD1-3 expression at gene level as well as at protein level in all samples tested. HBD1 and HBD3 messenger RNA (mRNA) levels were downregulated in SAR patients compared to healthy individuals. All HBDs were found in NAL fluids. SAR patients having completed 3 years of ASIT displayed higher levels of HBD1 and HBD2 than before treatment, whereas levels of HBD3 were unaffected. CONCLUSION: The present study demonstrates an upregulation of HBD1 and HBD2 in SAR patients after completion of ASIT. This may reflect the importance of an intact innate immune response as part of our defense against infections among allergic individuals. (Less)
Please use this url to cite or link to this publication:
author
; and
organization
publishing date
type
Contribution to journal
publication status
published
subject
keywords
allergy immunotherapy, allergic rhinitis, rhinitis, skin prick test, subcutaneous immunotherapy
in
International Forum of Allergy & Rhinology
volume
3
issue
2
pages
99 - 103
publisher
Wiley-Blackwell
external identifiers
  • wos:000315141700005
  • pmid:23255498
  • scopus:84873935693
  • pmid:23255498
ISSN
2042-6984
DOI
10.1002/alr.21127
language
English
LU publication?
yes
id
4957600f-ce91-4c37-bb08-9ac25c2b6a2c (old id 3347042)
alternative location
http://www.ncbi.nlm.nih.gov/pubmed/23255498?dopt=Abstract
date added to LUP
2016-04-01 14:29:59
date last changed
2022-01-28 00:57:23
@article{4957600f-ce91-4c37-bb08-9ac25c2b6a2c,
  abstract     = {{BACKGROUND: Antimicrobial peptides (AMPs) are important actors in the innate immune system. One class of AMPs is the human β-defensins (HBDs), a group of small peptides with a broad spectrum of antimicrobial activities. Expression of HBDs is downregulated in different manifestations of allergic disease. In this study, we examine whether allergen-specific immunotherapy (ASIT) affects the nasal levels of HBDs in patients with seasonal allergic rhinitis (SAR). METHODS: Nasal biopsies were examined for the occurrence of HBD1-3 with real-time reverse-transcription polymerase chain reaction (RT-PCR) and immunohistochemistry. Nasal lavage (NAL) fluids from healthy individuals, untreated SAR patients and SAR patients before and after ASIT were analyzed for levels of HBD1-3 using enzyme-linked immunosorbent assay (ELISA). RESULTS: Examination of nasal biopsies revealed HBD1-3 expression at gene level as well as at protein level in all samples tested. HBD1 and HBD3 messenger RNA (mRNA) levels were downregulated in SAR patients compared to healthy individuals. All HBDs were found in NAL fluids. SAR patients having completed 3 years of ASIT displayed higher levels of HBD1 and HBD2 than before treatment, whereas levels of HBD3 were unaffected. CONCLUSION: The present study demonstrates an upregulation of HBD1 and HBD2 in SAR patients after completion of ASIT. This may reflect the importance of an intact innate immune response as part of our defense against infections among allergic individuals.}},
  author       = {{Bogefors, Jesper and Kvarnhammar, Anne Månsson and Cardell, Lars-Olaf}},
  issn         = {{2042-6984}},
  keywords     = {{allergy immunotherapy; allergic rhinitis; rhinitis; skin prick test; subcutaneous immunotherapy}},
  language     = {{eng}},
  number       = {{2}},
  pages        = {{99--103}},
  publisher    = {{Wiley-Blackwell}},
  series       = {{International Forum of Allergy & Rhinology}},
  title        = {{Upregulated levels of human β-defensins in patients with seasonal allergic rhinitis after allergen-specific immunotherapy treatment.}},
  url          = {{http://dx.doi.org/10.1002/alr.21127}},
  doi          = {{10.1002/alr.21127}},
  volume       = {{3}},
  year         = {{2013}},
}